You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDomoic Acid
Accession NumberDB02852  (EXPT01248)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
Synonyms
(-)-domoic acid
L-domoic acid
External Identifiers
  • NSC-288031
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIM02525818H
CAS number14277-97-5
WeightAverage: 311.3303
Monoisotopic: 311.136887409
Chemical FormulaC15H21NO6
InChI KeyVZFRNCSOCOPNDB-AOKDLOFSSA-N
InChI
InChI=1S/C15H21NO6/c1-8(4-3-5-9(2)14(19)20)11-7-16-13(15(21)22)10(11)6-12(17)18/h3-5,9-11,13,16H,6-7H2,1-2H3,(H,17,18)(H,19,20)(H,21,22)/b5-3+,8-4-/t9-,10+,11-,13+/m1/s1
IUPAC Name
(2S,3S,4S)-4-[(2Z,4E,6R)-6-carboxy-6-methylhexa-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
SMILES
[H]\C(\C(\[H])=C(\C)[C@@]1([H])CN[C@]([H])(C(O)=O)[C@@]1([H])CC(O)=O)=C(\[H])[C@@]([H])(C)C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Glutamate receptor ionotropic, kainate 2ProteinunknownNot AvailableHumanQ13002 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinDomoic Acid may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Domoic Acid.Investigational
AmikacinAmikacin may increase the respiratory depressant activities of Domoic Acid.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Domoic Acid.Approved, Investigational
annamycinannamycin may increase the respiratory depressant activities of Domoic Acid.Investigational
AnvirzelDomoic Acid may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Domoic Acid.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Domoic Acid.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Domoic Acid.Approved, Investigational
Botulinum Toxin Type BDomoic Acid may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Domoic Acid.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Domoic Acid.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
ColistimethateColistimethate may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Domoic Acid.Approved, Investigational, Vet Approved
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Domoic Acid.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Domoic Acid.Approved
DeslanosideDomoic Acid may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinDomoic Acid may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinDomoic Acid may increase the arrhythmogenic activities of Digoxin.Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Domoic Acid.Vet Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Domoic Acid.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Domoic Acid.Approved, Investigational, Vet Approved
EpirubicinEpirubicin may increase the respiratory depressant activities of Domoic Acid.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Domoic Acid.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Domoic Acid.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
GeneticinGeneticin may increase the respiratory depressant activities of Domoic Acid.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Domoic Acid.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Domoic Acid.Experimental
Hygromycin BHygromycin B may increase the respiratory depressant activities of Domoic Acid.Vet Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Domoic Acid.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Domoic Acid.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Domoic Acid.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Domoic Acid.Approved
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Domoic Acid.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Domoic Acid.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Domoic Acid.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Domoic Acid.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Domoic Acid.Approved, Investigational
NeamineNeamine may increase the respiratory depressant activities of Domoic Acid.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Domoic Acid.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Domoic Acid.Approved
OuabainDomoic Acid may increase the arrhythmogenic activities of Ouabain.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Domoic Acid.Approved, Investigational
PirarubicinPirarubicin may increase the respiratory depressant activities of Domoic Acid.Investigational
PiretanidePiretanide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
PlicamycinPlicamycin may increase the respiratory depressant activities of Domoic Acid.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
ProcainamideProcainamide may increase the neuromuscular blocking activities of Domoic Acid.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Domoic Acid.Experimental
QuinidineQuinidine may increase the neuromuscular blocking activities of Domoic Acid.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Domoic Acid.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Domoic Acid.Approved
SisomicinSisomicin may increase the respiratory depressant activities of Domoic Acid.Investigational
SP1049CSP1049C may increase the respiratory depressant activities of Domoic Acid.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Domoic Acid.Approved, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Domoic Acid.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Domoic Acid.Approved
TetracyclineTetracycline may increase the neuromuscular blocking activities of Domoic Acid.Approved, Vet Approved
TobramycinTobramycin may increase the respiratory depressant activities of Domoic Acid.Approved, Investigational
TorasemideTorasemide may decrease the neuromuscular blocking activities of Domoic Acid.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Domoic Acid.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Domoic Acid.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8955
Blood Brain Barrier+0.5836
Caco-2 permeable-0.6537
P-glycoprotein substrateSubstrate0.6594
P-glycoprotein inhibitor INon-inhibitor0.914
P-glycoprotein inhibitor IINon-inhibitor0.9679
Renal organic cation transporterNon-inhibitor0.8929
CYP450 2C9 substrateNon-substrate0.8777
CYP450 2D6 substrateNon-substrate0.8096
CYP450 3A4 substrateNon-substrate0.5718
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.913
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.918
CYP450 3A4 inhibitorNon-inhibitor0.9855
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9836
Ames testNon AMES toxic0.8572
CarcinogenicityNon-carcinogens0.9473
BiodegradationNot ready biodegradable0.6119
Rat acute toxicity2.4199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9349
hERG inhibition (predictor II)Non-inhibitor0.9385
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.759 mg/mLALOGPS
logP-0.23ALOGPS
logP-1.8ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)1.68ChemAxon
pKa (Strongest Basic)11.59ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area123.93 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity79.03 m3·mol-1ChemAxon
Polarizability31.25 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as kainoids. These are non-proteigenous amino acids with a structure characterized by the presence of a pyrrolidine ring bearing two dicarboxylic acid groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentKainoids
Alternative Parents
Substituents
  • Kainoid skeleton
  • L-alpha-amino acid
  • Alpha-amino acid or derivatives
  • Alpha-amino acid
  • Tricarboxylic acid or derivatives
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • Pyrrolidine
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23